|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||198.56 - 203.60|
|52 Week Range||149.00 - 220.45|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
UnitedHealth Group Chief Scientific Officer Ken Ehlert joins Yahoo Finance’s Anjalee Khemlani and Seana Smith to discuss the new testing kit that will enable patients to test themselves for the virus at home.
Chief Financial Analyst at Bankrate.com Greg McBride joins Yahoo Finance’s Zack Guzman, Emily McCormick and Clearnomics Founder & CEO James Liu on YFi PM to discuss the response to the coronavirus as cases surpass 1,700 in the United States.
Cases of coronavirus surpassed 100,000 worldwide, with New York cases tripling in just 48 hours. Yahoo Finance’s Anjalee Khemlani breaks down the details with Seana Smith.
Quest Diagnostics announced it will begin screening for the coronavirus. Yahoo Finance’s Anjalee Khemlani joins Seana Smith on The Ticker to discuss.
Inovio shares are rising after its CEO says the company could deliver a million doses of its coronavirus vaccine by the end of the year. Yahoo Finance’s Anjalee Khemlani joins Seana Smith to discuss on the Ticker to discuss the details.
President Trump is putting pressure on the pharmaceutical industry to ‘accelerate’ their work on a vaccine for COVID-19. This comes as the FDA updated its policy to allow hundreds of American hospital labs to test for the coronavirus. Co-Diagnostics CEO Dwight Egan joins Yahoo Finance’s Seana Smith on The Ticker to discuss his company's involvement in testing for the coronavirus.
Health and Human Services Secretary Alex Azar told Congress that at least 40 public health labs are ready to test for the coronavirus. Yahoo Finance’s Anjalee Khemlani joins Dan Roberts and Kristin Myers, along with BigEyedWish Founder Ian Wishingrad, to discuss on YFi PM.
Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies Corporation (NASDAQ:ADPT) will participate in a webinar hosted by Bernstein on Thursday, April 9 at 8 a.m. PT (11 a.m. ET) where David M. Reese, M.D., executive vice president of Research and Development at Amgen and Harlan Robins, PhD, chief scientific officer and co-founder at Adaptive, will discuss the companies' strategic collaboration to develop a therapeutic to prevent or treat COVID-19.
U.S. biotechnology company Amgen Inc. (AMGN) is teaming up with Adaptive Biotechnologies Corp. (ADPT) to discover a drug to potentially treat coronavirus patients.The two companies announced Thursday they signed a Memorandum of Understanding to enable them to start work immediately due to the rapid spread of the coronavirus around the world. Terms of the agreement are not being disclosed. Amgen and Adaptive Biotechnologies join a list of companies partnering up to develop a COVID-19 drug.The collaboration brings together Adaptive's proprietary immune medicine platform for the identification of virus-neutralizing antibodies with Amgen's expertise in immunology and novel antibody therapy development.“Working with Adaptive and using their viral-neutralizing antibody platform will expedite our ability to bring a promising new medicine into clinical trials as quickly as possible," said Robert A. Bradway, chairman and chief executive officer at Amgen.The partnership will combine their expertise to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the disease and can be given to people who have heightened risk of exposure to SARS-CoV-2, such as healthcare workers.Overall Wall Street analysts have a Moderate Buy consensus rating for Amgen split into 14 Buys, 4 Holds and 1 Sell. The $246.56 average price target sees room for 18% upside potential in the stock in the next 12 months (See Amgen stock analysis on TipRanks)Related News: Demand for Roche’s COVID-19 Tests Exceeding Capacity; 5-Star Analyst Says ‘Buy’ CryoLife Pre-Releases Low 1Q20 Revenues, Pulls FY20 Guidance Analyst Impressed by Sorrento’s COVID-19 Pipeline, Says ‘Buy’ More recent articles from Smarter Analyst: * Chembio Spikes 8% As Covid-19 Antibody Test Picked For Study * Amazon Begins Building Covid-19 Testing Facility * Zscaler Announces Intent to Acquire CSPM Company Cloudneeti * Tesla Scored Record China Sales In March, Says Industry Association
Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. The mutually exclusive collaboration brings together Adaptive's proprietary immune medicine platform for the identification of virus-neutralizing antibodies with Amgen's expertise in immunology and novel antibody therapy development. Given the rapidly rising incidence of COVID-19 around the world, the companies will begin work immediately and finalize financial details and terms in the coming weeks.
Amgen (NASDAQ:AMGN) today announced that it has consummated the purchase from Astellas of 49% of shares of Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas established in 2013. AABP, which is now a wholly-owned Amgen affiliate in Japan renamed Amgen K.K., has enabled Amgen to build a strong presence in Japan as it advances treatments for serious illnesses.
Amgen (NASDAQ:AMGN) today announced positive results from the EvolocumaB Effect on LDL-C LowerIng in SubJEcts with Human Immunodeficiency ViRus and INcreased Cardiovascular RisK (BEIJERINCK) study evaluating the efficacy and safety of Repatha® (evolocumab) in patients who are human immunodeficiency virus-positive (HIV+) and have high low-density lipoprotein cholesterol (LDL-C) despite stable background lipid-lowering therapy.1 The study demonstrated that treatment with Repatha significantly reduced LDL-C. The results were featured as an oral presentation during the virtual American College of Cardiology's 69th Annual Scientific Session from March 28-30, 2020 with publication in the Journal of the American College of Cardiology (JACC) on March 30, 2020.
With the COVID-19 crisis sending the U.S. economy in a recession, we're looking at what companies managed to thrive during the last recession for guidance.
Amgen (NASDAQ:AMGN) and the Amgen Foundation today announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in communities impacted by the COVID-19 pandemic. The funds will be used to support emergency response efforts in Amgen's U.S. and international communities, patient-focused organizations that are mounting their own response efforts, and international relief efforts by Direct Relief and International Medical Corps. The Amgen Foundation will also match donations made by Amgen staff around the globe who wish to contribute their own funds to the relief efforts.
(Bloomberg Opinion) -- The $8.3 billion spending bill that President Donald Trump signed last week to address the coronavirus crisis contains a provision that could be costly: When a vaccine for the virus becomes available, the law says, the government can spend no more than a “fair and reasonable” price for it. But it does not require the drugmaker to accept such a payment.The law includes a pricing mechanism, but it relies in part on comparisons with other vaccine prices, and these vary widely: Medicare reimburses about $56 for Sanofi’s influenza vaccine, $500 per course for Merck’s human papilloma vaccine, and $5,000 per injection for Amgen’s melanoma vaccine.Inevitably, then, when an effective, desperately needed vaccine is ready, we can expect a pricing standoff. To avoid this, the government should buy vaccines now, even before they’re invented. This would guarantee a good price for the government, and it would benefit drugmakers by ensuring a market for their products. Our government routinely procures items that are not yet designed and built. Engines for fighter jets are purchased when they are sketches on paper, as are federal office buildings. Vaccines needed for the developing world are sometimes pre-purchased through advanced market commitments. In all cases the contracts specify minimum requirements for the ultimate product.It’s easy to imagine the profile for a Covid-19 vaccine. First, it would need to be effective enough to curtail spread. Early vaccines rarely work on everyone, but even modest effectiveness would provide large benefits to public health. And while the immunity conferred by a vaccine can wane, what’s needed most immediately is near-term protection. Expected side effects should be rare, and monitoring for severe ones should be required.We would also need this vaccine to be produced at population scale within a year. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, has said this is a scientifically achievable timeline. Production, distribution, outreach and delivery would all be part of a staged contract.Using these specifications, the government would solicit bids, and each responding vaccine developer would propose the price it would charge for developing and delivering a vaccine, either alone or with partners. Because any one vaccine is unlikely to be perfect or perfectly supplied, we should select three or more winners.The alternative is to wait for the U.S. pharmaceutical industry to develop a vaccine on its own, relying on existing market mechanisms to protect against the usual risks of drug development. The first of these is the risk inherent in investing money and time on a drug that may turn out not to be effective. Vaccine science mitigates this threat. The Coalition for Epidemic Preparedness Innovations has already developed eight promising vaccine candidates against Covid-19. And 25 companies are ready to work on a vaccine.The second uncertainty is whether there will turn out to be a market for the products that drugmakers create. The government contract approach we propose mitigates that possibility. Both of us know from experience the problems that arise when unaffordability keeps an essential medical treatment out of reach. We helped develop the subscription model that Louisiana and the state of Washington use to finance expensive drugs to treat hepatitis C: The states pay a flat fee in return for as many courses of treatment as they need.The federal government could follow a similar “Netflix financing” model to pay a single price to vaccinate the population against the coronavirus.We don’t know how much such a contract will cost. But asking for bids will lead companies to put forward their best prices. The winners will make money (including by selling their vaccines overseas) while showing off their scientific prowess and the important role they play in public health. And the federal government can make sure everyone in the U.S. is protected against Covid-19.To contact the authors of this story: Peter B. Bach at email@example.comMark Trusheim at firstname.lastname@example.orgTo contact the editor responsible for this story: Mary Duenwald at email@example.comThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Peter B. Bach, a physician, directs the Drug Pricing Lab at Memorial Sloan Kettering Cancer Center in New York. Mark Trusheim is a visiting scientist at the MIT Sloan School of Management. For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Coronavirus is probably the 1 concern in investors’ minds right now. It should be. On February 27th we publish an article with the title "Recession is Imminent: We Need A Travel Ban NOW". We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the second quarter of 2020. The dividend will be paid on June 8, 2020, to all stockholders of record as of the close of business on May 18, 2020.
Amgen (NASDAQ:AMGN) will present at the Cowen 40th Annual Healthcare Conference at 11:20 a.m. ET on Monday, March 2, 2020 in Boston. Peter H. Griffith, executive vice president and chief financial officer, and Murdo Gordon, executive vice president of Global Commercial Operations at Amgen will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
Amgen (NASDAQ:AMGN), Cytokinetics, Incorporated (NASDAQ:CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the second and final planned interim analysis, which included consideration of pre-specified criteria for futility and superiority. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial of omecamtiv mecarbil continue without changes to its conduct.
Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2019 financial results on Thursday, Jan. 30, 2020, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
The Amgen Foundation and the Faculty of Arts and Sciences at Harvard University (Harvard FAS) today announced the global launch of LabXchange™, a free online science education platform that provides users with access to personalized instruction, virtual lab experiences and networking opportunities across the global scientific community. LabXchange is purpose-built to drive more inclusion in the scientific process and spark collaboration to build creative, team-based approaches to real-world problems.
Amgen (NASDAQ: AMGN) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood- and tissue-based companion diagnostics (CDx), respectively, for investigational cancer treatment AMG 510. AMG 510 is the first KRASG12C inhibitor to advance to the clinic for investigation in treatment of multiple tumor types. KRAS G12C is one of the most frequently mutated oncogenes in human cancers. The agreements with both companies will initially focus on CDx tests for non-small cell lung cancer (NSCLC) but allow for further development of the diagnostic tests for Amgen's other oncology clinical development programs.